达拉图穆马
多发性骨髓瘤
医学
疾病
内科学
免疫学
肿瘤科
重症监护医学
血液学
来那度胺
作者
Tomáš Jelı́nek,Tereza Ševčíková,David Žihala,Tereza Popková,Veronika Kapustová,Lucie Broskevičová,Lenka Čápková,Lucie Říhová,Renata Bezděková,Sabina Ševčı́ková,Vladimír Židlík,Martin Havel,Hana Plonková,Alexandra Jungová,Jiří Minařík,Martin Štork,Luděk Pour,Petr Pavlíček,Ivan Špıčka,Vladimír Maisnar
出处
期刊:Leukemia
[Springer Nature]
日期:2021-07-10
卷期号:36 (1): 288-291
被引量:35
标识
DOI:10.1038/s41375-021-01343-w
摘要
The treatment of multiple myeloma (MM) has changed
substantially during the past two decades. The incorporation of
novel agents into therapeutic strategies has resulted in
prolonged overall survival of MM patients with approximately
15% of them being considered operationally cured.
科研通智能强力驱动
Strongly Powered by AbleSci AI